Generation Bio Co. logo
Generation Bio Co. GBIO

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Generation Bio Co. General and Administrative Expenses 2011-2026 | GBIO

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Generation Bio Co.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
50.8 M 44.5 M 33.9 M 22.6 M 12.2 M 9.18 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
50.8 M 9.18 M 28.8 M

Quarterly General and Administrative Expenses Generation Bio Co.

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
12.2 M 7.67 M 8.83 M - 9.18 M 9.52 M 10.4 M - 11.6 M 13 M 12.9 M - 11.5 M 10.1 M 9.79 M - 9.67 M 8.19 M 6.9 M - 5.66 M 4.31 M 4.64 M - 2.89 M 3.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
13 M 2.89 M 8.6 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
78.3 M - 2.43 % $ 254 M germanyGermany
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
5.51 M $ 3.6 1.34 % $ 8.66 B australiaAustralia
Aytu BioScience Aytu BioScience
AYTU
17.4 M $ 2.66 - $ 16.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
286 M $ 91.28 - $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
900 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
1.4 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
16.2 M - 2.54 % $ 160 B franceFrance
Burford Capital Limited Burford Capital Limited
BUR
99.3 M $ 4.48 - $ 736 M britainBritain
Biophytis SA Biophytis SA
BPTS
7.15 M - -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
80.9 M $ 1.85 - $ 353 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
4.95 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
4.66 M - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
89.7 M - -24.86 % $ 820 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
101 M $ 1.67 - $ 196 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
43.8 M $ 31.37 - $ 2.08 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
5.94 M $ 0.44 - $ 5.04 M israelIsrael
Advaxis Advaxis
ADXS
12.2 M - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
63.1 M - - $ 86.2 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
6.21 M $ 2.32 - $ 1.03 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
25.8 M - - - russiaRussia
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
63.1 M $ 24.98 - $ 3.05 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
15.2 M $ 10.14 - $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
14.2 M $ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
14 M $ 0.53 - $ 6.98 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
191 M $ 37.7 - $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
73.5 M $ 49.15 - $ 4.42 B schweizSchweiz
Aeterna Zentaris Aeterna Zentaris
AEZS
5.92 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
11 M - -10.17 % $ 12.2 K usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
29.8 M $ 4.4 - $ 607 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
18.2 M $ 0.86 - $ 5.79 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
47.9 M - - $ 1.01 B usaUSA
Cue Biopharma Cue Biopharma
CUE
16.2 M $ 0.18 - $ 17.1 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
17 M - - $ 26.5 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
32.8 M $ 20.36 - $ 2.84 B franceFrance
AIkido Pharma AIkido Pharma
AIKI
23.8 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
13.4 M - -45.71 % $ 1.2 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
105 M $ 19.38 - $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
890 K $ 0.87 -2.8 % $ 31.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
37.9 M - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
100 M - - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
9.28 M $ 3.54 - $ 238 B britainBritain
Akouos Akouos
AKUS
22.2 M - 0.23 % $ 488 M usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
4.89 M $ 1.19 - $ 55.5 M israelIsrael
Equillium Equillium
EQ
10.8 M $ 2.01 - $ 115 M usaUSA
Allakos Allakos
ALLK
45.1 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
12.7 M - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
1.21 B $ 330.34 - $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
18 M - - $ 2.17 B usaUSA
Fate Therapeutics Fate Therapeutics
FATE
46.5 M $ 1.19 - $ 141 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
10.9 M - 10.36 % $ 9.8 M usaUSA